- Home
- » Tags
- » Tezepelumab
Top View
- Medimmune: Leading the Revolution in Respiratory Medicine with Biologics
- Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
- Shareholders 2017 Letter to Shareholders
- Biosimilars: Impact, Lessons Learned, and Opportunities
- (CHMP) Agenda for the Meeting on 21-24 June 2021
- Tezepelumab for Severe Asthma Background
- 2021 Jp Morgan Healthcare Conference: Preview
- A View Into Upcoming Specialty & Traditional Drugs
- Treatment of Atopic Dermatitis: What’S New?
- Kinase Inhibition in Autoimmunity and Inflammation
- Rxoutlook® 2Nd Quarter 2021
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
- Atopic Dermatitis 9
- A Phase 3, Multicentre, Randomized, Double-Blind, Placebo-Controlled
- 313 Needs Assessment for an Infant and Toddler Food Allergy
- Statins Linked to Lower Death Rates in COPD Tezepelumab Reduces
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
- Biologics for Atopic Diseases: Indication, Side Effect Management, and New Developments
- Sustaining Innovation Analyst Day
- 2018 Letter to Shareholders
- 2020 Medicines in Development for Children
- A View Into Upcoming Specialty & Traditional Drugs
- Clinical Trials Appendix Q1 2021 Results Update
- (INN) for Biological and Biotechnological Substances
- January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- April 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- WO 2018/200533 Al 01 November 2018 (01.11.2018) W !P O PCT
- To Benralizumab for Severe Asthma: Pooled Analysis of the SIROCCO and CALIMA Studies
- Monoclonal Antibodies in Type 2 Asthma: a Systematic Review and Network Meta- Analysis Ahmed Edris1, Silke De Feyter1,2, Tania Maes2, Guy Joos2 and Lies Lahousse1*
- 2019 Medicines in Development for Asthma and Allergy
- Antibodies to Watch in 2018